EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria
BJUI Compass · 2026-03 · 7 (3)
DOI: 10.1002/bco2.70178 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 06.03.2026. Verfasst von Tae Jeong Oh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Genomictree, Inc. Daejeon Republic of Korea. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aims to develop and clinically evaluate EarlyTect BCD Plus, a urine‐based assay measuring two methylation sites of the PENK gene, and to assess its diagnostic performance and clinical utility according to haematuria risk stratification. Materials and Methods A dual‐target quantitative methylation‐specific PCR assay was optimized using the PENK gene and evaluated in 892 patients with haematuria from Korea and the United States who underwent cystoscopy and histopathology. Urine DNA was analysed for two PENK methylation markers, and test results were interpreted using a combined algorithm. Diagnostic accuracy was assessed, and clinical utility was further analysed for patients stratified by the 2025 AUA/SUFU haematuria guideline risk categories.
Results
In the pooled cohort (gross haematuria, n = 509; microhaematuria, n = 366; unspecified haematuria, n = 17), EarlyTect BCD Plus achieved a sensitivity of 87.7% (95% CI, 81.5%–92.5%), specificity of 82.5% (95% CI, 79.6%–85.2%) and negative predictive value (NPV) of 97.0% (95% CI, 95.5%–98.0%). Sensitivity for Ta‐LG tumours improved to 60.5% compared with the original single‐marker assay, while high‐grade tumours were detected with 96.6% sensitivity. In the intermediate‐risk group, NPVs were 99.1% for all BC and 100% for high‐grade BC.
Conclusions
EarlyTect BCD Plus significantly enhances detection of Ta‐LG bladder cancer while maintaining high specificity. Its high NPV supports use as a non‐invasive adjunct and triage tool, allowing deferral of cystoscopy in selected haematuria patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomictree, Inc. Daejeon Republic of Korea.
- Promis Diagnostics, Inc. Irvine California USA.
- Department of Medicine University of California, Riverside Riverside California USA.
- Pathology & Laboratory Medicine Service VA Greater Los Angeles Medical Center Los Angeles California USA.
- Department of Urology VA Greater Los Angeles Medical Center Los Angeles California USA.
- Department of Urology David Geffen School of Medicine at UCLA Los Angeles California USA.
ORCID-Profile: Theo deVos
Zitieren
APA
Oh, T. J., Bang, B. R., Hwang, J. H., Seo, Y., Kim, S., Gu, S., Beqaj, S., deVos, T., Lee, J. J., Zhong, J., Shirk, J. D., Ke, K. W., Vallone, J., & An, S. (2026). EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria. BJUI Compass, 7(3). https://doi.org/10.1002/bco2.70178
Vancouver
Oh TJ, Bang BR, Hwang JH, Seo Y, Kim S, Gu S, et al. EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria. BJUI Compass. 2026;7(3). doi:10.1002/bco2.70178
BibTeX
@article{Oh2026,
author = {Oh, Tae Jeong and Bang, Bo-Ram and Hwang, Jae Hee and Seo, Yangyei and Kim, Seoyong and Gu, Sujin and Beqaj, Safedin and deVos, Theo and Lee, Justin Junguek and Zhong, Jin and Shirk, Joseph D and Ke, Katelyn W and Vallone, John and An, Sungwhan},
title = {EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria},
journal = {BJUI Compass},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/bco2.70178}
}
EUVIMED